

The role of phospholipid and factor VIII_a in the activation of bovine factor X

Citation for published version (APA):

van Dieijen, G., Tans, G., Rosing, J., & Hemker, H. C. (1981). The role of phospholipid and factor VIII_a in the activation of bovine factor X. *Journal of Biological Chemistry*, 256(7), 3433-3442.

Document status and date:

Published: 01/01/1981

Document Version:

Publisher's PDF, also known as Version of record

Please check the document version of this publication:

- A submitted manuscript is the version of the article upon submission and before peer-review. There can be important differences between the submitted version and the official published version of record. People interested in the research are advised to contact the author for the final version of the publication, or visit the DOI to the publisher's website.
- The final author version and the galley proof are versions of the publication after peer review.
- The final published version features the final layout of the paper including the volume, issue and page numbers.

[Link to publication](#)

General rights

Copyright and moral rights for the publications made accessible in the public portal are retained by the authors and/or other copyright owners and it is a condition of accessing publications that users recognise and abide by the legal requirements associated with these rights.

- Users may download and print one copy of any publication from the public portal for the purpose of private study or research.
- You may not further distribute the material or use it for any profit-making activity or commercial gain
- You may freely distribute the URL identifying the publication in the public portal.

If the publication is distributed under the terms of Article 25fa of the Dutch Copyright Act, indicated by the "Taverne" license above, please follow below link for the End User Agreement:

www.umlib.nl/taverne-license

Take down policy

If you believe that this document breaches copyright please contact us at:

repository@maastrichtuniversity.nl

providing details and we will investigate your claim.

The Role of Phospholipid and Factor VIII_a in the Activation of Bovine Factor X*

(Received for publication, August 5, 1980, and in revised form, November 18, 1980)

Gerbrand van Dieijen, Guido Tans, Jan Rosing, and H. Coenraad Hemker

From the Department of Biochemistry, Biomedical Centre, State University of Limburg, Maastricht, The Netherlands

The kinetic parameters of bovine factor X activation by bovine factor IX_a have been determined in the absence and presence of Ca²⁺, thrombin-activated bovine factor VIII (VIII_a), and phospholipid (dioleoylphosphatidylcholine/dioleoylphosphatidylserine, 75/25; mol/mol). Factor IX_a in the absence of Ca²⁺, factor VIII_a, and phospholipid is able to catalyze factor X activation. The K_m for factor X is 299 μM which is well above its concentration in bovine plasma, about 0.2 μM . The V_{max} of factor X_a formation is 0.0022 mol of X_a·min⁻¹·mol of IX_a⁻¹ under these conditions. Addition of Ca²⁺ has little effect on the kinetic constants of factor X activation by factor IX_a. In the presence of 10 mM CaCl₂ the K_m for factor X is 181 μM , and the V_{max} is 0.0105 mol of X_a·min⁻¹·mol of IX_a⁻¹. The presence of 10 μM phospholipid dramatically decreases the K_m for factor X to 0.058 μM , and the V_{max} becomes 0.0025 mol of X_a·min⁻¹·mol of IX_a⁻¹. The V_{max} of factor X_a formation slightly increases when more phospholipid is present in our experiments, and there is a considerable increase of the K_m for factor X at higher phospholipid concentrations. Therefore, the K_m measured in the presence of phospholipid has to be regarded as an apparent K_m . The possible explanations for this phenomenon are discussed.

For the complete factor X-activating complex (*i.e.* factor IX_a, factor VIII_a, Ca²⁺, and 10 μM phospholipid) the K_m for factor X is 0.0063 μM , and the V_{max} is raised 200,000-fold to 500 mol of X_a·min⁻¹·mol of IX_a⁻¹. In order to exert its stimulating effect on factor X activation factor VIII has to be activated with thrombin. Our results show that factor IX_a is an enzyme which can activate factor X at a very low rate. The stimulating effect of phospholipid in factor X activation is mainly due to an effect on the K_m for factor X, bringing it within the range of the plasma concentration. The stimulatory effect of factor VIII_a is explained by its 200,000-fold increase of the V_{max} of factor X_a formation.

Blood coagulation factor X¹ is a plasma glycoprotein that, during the clotting process, is converted into the serine protease factor X_a through proteolytic cleavage of a single peptide bond (1, 2). Factor X_a is the enzyme that, during the coagulation process, activates prothrombin to thrombin in a reaction accelerated by factor V_a, calcium ions, and phospholipid.

Under physiological conditions, the activation of factor X can be accomplished in both the extrinsic and intrinsic pathways of blood coagulation. In the extrinsic pathway factor X

is activated by a complex of factor VII, tissue factor, and calcium ions (for a review, see Ref. 3), whereas the activation of factor X via the intrinsic pathway involves the interaction of factor IX_a, factor VIII, calcium ions, and phospholipid.

It is now generally accepted that factor IX_a, factor VIII, phospholipid, and calcium ions form a complex (1, 4-11), in which factor IX_a likely is the enzyme responsible for factor X activation, since it is highly homologous to other serine proteases involved in blood coagulation (12, 13), and factor VIII, phospholipid, and calcium ions function as cofactors (14). Thus it is tempting to speculate that the roles of the components of the intrinsic factor X activator are analogous to those of factors X_a, V_a, phospholipid, and calcium ions in the prothrombin-activating complex (7, 8, 9, 11, 14).

Since the activity of factor VIII is considerably enhanced by preincubation with small amounts of thrombin, it is likely that factor VIII participates in the factor X-activating complex in an activated form (15). Davie *et al.* (16, 18) reported that factor VIII can also be activated with factor X_a. Of interest is the finding of Vehar and Davie (17, 18) that thrombin-activated factor VIII is inhibited by diisopropylphosphorofluoridate and antithrombin III, which may have consequences for the way in which factor VIII functions in factor X activation.

In addition to factor IX_a and factor VIII, the factor X-activating complex requires negatively charged phospholipid and calcium ions. It has been shown that the proteins have to be adsorbed to the phospholipid bilayer surface during the activation reaction (6-11, 14). Both vitamin K-dependent clotting factors IX_a and X bind to the phospholipid surface via calcium bridges between the γ -carboxyglutamic acid-containing domains of the proteins and the polar head groups of the phospholipid (for a recent review on the role of phospholipid in blood coagulation, see Ref. 19).

The purpose of the experiments described in this paper is to examine the role of the various components of the intrinsic factor X-activating complex by an analysis of the kinetics of factor X activation. In the past, a direct study of this reaction has been difficult for a number of reasons. Methods for purification of the proteins involved were not available, and factor X activation could only be followed by a coagulation assay. Such an assay is, however, only possible in the presence of other coagulation factors and may be influenced by a number of feedback reactions.

A more detailed study of the activation reaction is now possible because methods are available to purify the proteins involved, and factor X_a formation can be measured directly either with the chromogenic substrate S 2222² (20) or through

* The costs of publication of this article were defrayed in part by the payment of page charges. This article must therefore be hereby marked "advertisement" in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.

¹ The nomenclature of the blood coagulation factors used is that recommended by the Task Force on Nomenclature of Blood Clotting Zymogens and Zymogen Intermediates.

² The abbreviations used are: S 2222, *N*-benzoyl-L-isoleucyl-L-glutamyl-glycyl-L-arginine-*p*-nitroanilide hydrochloride; S 2238, *H*-D-phenylalanyl-L-pipecolyl-L-arginine-*p*-nitroanilide dihydrochloride; *p*-NPGB, *p*-nitrophenyl-*p'*-guanidinobenzoate hydrochloride; RVV-X, purified factor X activator from Russell's viper venom; STI, soybean trypsin inhibitor.

the release of an acid-soluble radiolabeled activation peptide (21). Fujikawa *et al.* (1) have shown that the activation of factor X is the result of the cleavage of the same arginyl-iso-leucine peptide bond in the heavy chain of factor X both with factor IX_a and factor VIII or tissue factor and factor VII_a as activator. Suomela and Blombäck (20) and Hultin and Nemerson (22) have shown that factor X is activated at a very low rate by factor IX_a in the presence of phospholipid and calcium ions. Addition of thrombin-activated factor VIII increased the rate of factor X_a formation more than 500-fold (22).

Brown *et al.* (23) reported a K_m for factor X of about 0.2 μM when factor X is activated by human factor IX_a and bovine factor VIII in the presence of calcium ions and phospholipid. No activation of factor X by factor IX_a in the absence of accessory components has yet been reported in the literature.

In this article, we present experiments designed to study the kinetics of intrinsic factor X activation. The approach is similar to that followed in a study on the kinetics of prothrombin activation reported earlier (24). Using purified clotting factors and an assay for factor X_a with chromogenic substrate, we are able to show factor X activation by factor IX_a alone and derive kinetic parameters (K_m for factor X and V_{max} for factor X_a formation) for this reaction. We determined the effects of phospholipid and factor VIII on these kinetic parameters. The results of this study allow a first attempt to explain the role of phospholipid and factor VIII_a in the mechanism of factor X activation and an appreciation of the contribution of the intrinsic pathway to thrombin formation *in vivo*.

EXPERIMENTAL PROCEDURES

Materials

S 2222 and S 2238 were purchased from AB Kabi Diagnostica, Stockholm, Sweden. *p*-NPGB was from Nutritional Biochemicals. Russell's viper venom, heparin sodium salt (grade I, 170 USP units/mg), STI, and ovalbumin were obtained from Sigma. DEAE-Sephadex A-50, Sephadex G-100 and G-25, Sepharose 4B and 6B, and CNBr-activated Sepharose 4B were from Pharmacia. AcA 44 was purchased from LKB. Trasylol was from Bayer, Leverkusen, Germany. Kaolin light was from BDH. STI was coupled to CNBr-activated Sepharose 4B following the method of Cuatrecasas (25). Heparin was coupled to Sepharose 4B according to the method of Cuatrecasas (25) as described by Fujikawa *et al.* (26). All reagents used were of the highest grade commercially available.

Methods

Proteins—Bovine factor IX was purified as described by Fujikawa *et al.* (26). Bovine factors X₁ and X₂ were prepared according to Fujikawa *et al.* (27). The factor IX, X₁, and X₂ preparations were homogeneous as determined by gel electrophoresis in the presence of sodium dodecyl sulfate. The specific activities of these preparations, as determined with a clotting assay, were 100 units/mg for factor X and 145 units/mg for factor IX, assuming 1 unit of factor X and 1 unit of factor IX to be present per ml of normal bovine plasma.

Partially purified contact product was prepared according to Nossel (28) and further purified by heparin-agarose affinity chromatography as suggested by Østerud and Rapaport (29). Contact product was applied to the heparin-agarose column (1.5 × 15 cm) in a buffer containing 0.05 M sodium acetate and 0.3 M NaCl at pH 5.5 and was eluted with a linear gradient of 0.3 to 1.0 M NaCl in 0.05 M sodium acetate at pH 5.5.

RVV-X was purified from the crude venom as described by Schiffman *et al.* (30). Bovine factor X_a was prepared from bovine factor X₂ using RVV-X according to the method of Fujikawa *et al.* (31).

Bovine factor IX_a was prepared by incubating factor IX (2 mg/ml) at 37°C with the purified contact product (38 $\mu\text{g}/\text{ml}$) in a buffer containing 50 mM Tris-HCl, 50 mM NaCl at pH 8.5 in the presence of 10 mM CaCl₂ (32). After 60 min of incubation EDTA and benzamidine were added to result in final concentrations of 15 mM and 20 mM, respectively. The reaction mixture was then applied to a column of DEAE-Sephadex A-50 (1.5 × 30 cm) in 50 mM Tris-HCl, 50 mM NaCl,

and 20 mM benzamidine at pH 7.9. Factor IX_a was eluted with a linear gradient of 50 mM to 400 mM NaCl (2 × 250 ml) in 50 mM Tris-HCl, 20 mM benzamidine at pH 7.9.

Bovine β factor X was prepared from factor X₂ by incubation of factor X₂ (3 mg/ml) with factor X_a (36 $\mu\text{g}/\text{ml}$) in the presence of 100 μM phospholipid vesicles (for preparation see below) in a buffer containing 175 mM NaCl, 10 mM CaCl₂, and 50 mM Tris-HCl at pH 7.9 at 37°C (*cf.* Ref. 33). Gel electrophoresis in the presence of sodium dodecyl sulfate showed that after 90 min of incubation all factor X₂ present was converted into β factor X and a small amount of β factor X_a. So after 90 min of incubation EDTA was added to a final concentration of 15 mM, and the reaction mixture was applied to an AcA 44 column (2.5 × 90 cm) in 0.1 M sodium citrate at pH 6.0. β Factor X was eluted with 0.1 M sodium citrate, pH 6.0. After pooling, the β factor X preparation was dialyzed against 175 mM NaCl, 50 mM Tris-HCl buffer at pH 7.9 and chromatographed on a STI-Sepharose column (1.5 × 10 cm) to remove factor X_a. β Factor X preparations were homogeneous as determined by gel electrophoresis in the presence of sodium dodecyl sulfate.

Thrombin was purified as a prothrombin activation product as described earlier (24).

For the preparation of factor VIII, 9 liters of blood were collected in plastic containers containing 1 liter of 0.1 M oxalate, 100 mM benzamidine, 20,000 units of heparin, and 100,000 Kallikrein Inhibitor Units of Trasylol. Plasma was obtained by centrifugation of the blood at 0°C for 25 min at 2000 × *g* in a MSE Mistral 6L centrifuge. BaSO₄ (100 mg/ml) was added to the plasma, and the suspension was stirred for 20 min at 4°C. The BaSO₄ was removed by centrifugation at 0°C for 20 min at 2000 × *g*. BaSO₄-treated plasma was stored at -70°C in 3-liter plastic containers before further use. After thawing and ethanol precipitation as described by Schmer *et al.* (34), the suspension was centrifuged for 20 min at 2000 × *g* at -2°C in a MSE Mistral 6L centrifuge. The precipitate containing factor VIII was dissolved in a buffer of 0.017 M barbituric acid, 0.125 M NaCl, 0.05 M 6-aminohexanoic acid at pH 7.0 at room temperature. This was then applied to two coupled Sepharose 6B columns (5 × 100 cm) (35).

Factor VIII was eluted at room temperature with the same barbituric acid buffer containing 0.02% NaN₃ at pH 7.0. After about 950 ml of eluate factor VIII activity appeared well separated from a large protein peak containing fibrinogen. The front of the peak (60 ml) was pooled, and the pooled eluate was centrifuged at 190,000 × *g* for 21 h in a MSE Superspeed 65 ultracentrifuge at 4°C. The pellet (factor VIII) was dissolved in 50 mM Tris-HCl, 175 mM NaCl at pH 7.9 to a concentration of 40 units/ml. Following this procedure the total recovery of factor VIII is about 2%. The specific activity of this preparation, measured with a clotting assay, is about 25 units/mg. The activity is raised 15-fold upon incubation with thrombin. The specific activity of purified factor VIII measured with a clotting assay is a minimum value, since it is dependent on the dilution of the factor VIII preparation. Higher values were obtained when higher dilutions were tested.

Factor VIII activities were measured in a one-stage coagulation assay in a factor VIII-deficient plasma prepared according to Chantarangkul *et al.* (36). Fifty- μl buffer containing 0.029 M sodium barbiturate, 0.029 M sodium acetate, 0.116 M NaCl (pH 7.4), 0.25 mg/ml of inosithine, and 0.5 mg/ml of kaolin (light) were incubated for 6 min at 37°C with 50 μl of the factor VIII reagent. Fifty μl of a factor VIII-containing sample was added followed by the addition of 50 μl of 0.033 M CaCl₂, and the clotting time was measured. Activities of factor VIII were expressed in units/ml assuming 1 unit/ml present in normal bovine plasma.

All protein preparations were stored at -70°C after dialysis against 50 mM Tris-HCl, 175 mM NaCl at pH 7.9. Before storage at -70°C, the factor X₁, X₂, βX , and IX preparations were passed through a column of STI-Sepharose (0.9 × 20 cm) to reduce the small amounts of factor X_a that might be present in these preparations. No thrombin or factor X_a could be detected in our protein preparations as determined with the chromogenic substrate S 2238 or with S 2222.

Protein Concentrations—Factor X_a concentrations were determined by active site titration with *p*-NPGB according to Smith (37). Factor IX_a concentrations were also determined by active site titration with *p*-NPGB (38). Factor X₁, X₂, and βX concentrations were determined after complete activation with RVV-X followed by active site titration with *p*-NPGB. When protein concentrations are expressed in milligrams per ml, they were calculated from the A_{280} using an $A_{280}^{1\%}$ of 14.9 and 14.3 for factors IX and IX_a (32) and of 12.4 for factors X₁, X₂ (39), and βX .

Phospholipids and Phospholipid Vesicle Preparations—Phos-

pholipid vesicle preparations were made from a mixture of 1,2-dioleoyl-*sn*-glycero-3-phosphoserine and 1,2-dioleoyl-*sn*-glycero-3-phosphocholine (25/75; mol/mol) in a buffer containing 50 mM Tris-HCl and 175 mM NaCl (pH 7.9) as described earlier (24).

Measurement of the Rates of Factor X_a Formation—Activation of factor X by factor IX_a at 37°C either in the presence or absence of phospholipid, CaCl₂, and/or factor VIII_a (for further experimental conditions see legends to the figures) was followed by transferring small aliquots of the reaction mixture after different time intervals to a cuvette (thermostated at 37°C) containing a buffer of 50 mM Tris-HCl, 175 mM NaCl, 0.5 mg/ml of ovalbumin, and 10 mM EDTA at pH 7.9 in such amounts that the final volume became 2 ml; 192 μM of the factor X_a-specific chromogenic substrate S 2222 was also present. Further reaction of factor IX_a with factor X is prevented by dilution and the presence of EDTA. Since factor IX_a has no amidase activity toward S 2222, the absorbance change recorded at 405–500 nm on an Aminco DW2 spectrophotometer (set in the dual wavelength mode) is a measure of the amount of factor X_a present in the aliquot.

From a calibration curve made with known amounts of active site-titrated factor X_a, determined under the same assay conditions as described above, the amount of factor X_a present in the aliquot can be calculated. The rate of factor X_a formation in the reaction mixture is calculated from the amounts of factor X_a present in the samples taken at different time intervals.

The amount of factor IX_a present in the incubation mixture was chosen such that less than 2% of the factor X added is converted during the experiment. Rates of factor X_a formation are expressed as mole factor X_a formed per min per mol of factor IX_a present as determined by active site titration with *p*-NPGFB.

For the construction of Lineweaver-Burk plots the rates of factor X_a formation were averaged from three independent determinations at each factor X concentration. *K_m* and *V_{max}* were determined by statistical analysis of the data as described by Eisenthal and Cornish-Bowden (40), and lines were drawn accordingly.

Gel Electrophoresis—Gel electrophoresis in the presence of sodium dodecyl sulfate was carried out as described in a previous paper (24).

RESULTS

The Kinetics of Factor X Activation in the Absence of Phospholipid and Factor VIII—Although there are no reports in the literature which demonstrate that factor IX_a alone is able to activate factor X, our kinetic experiments on prothrombin activation in solution (24), which showed a high *K_m* for the substrate prothrombin and a low *V_{max}*, made clear that it might be possible to activate factor X in solution at high factor X and factor IX_a concentrations. Fig. 1 shows that factor IX_a is indeed able to activate factor X in the absence of calcium ions, factor VIII, and phospholipid. Calcium ions stimulate the activation about 7-fold, and there is a rather broad optimum around 10 mM Ca²⁺. The Ca²⁺ titration curves are independent of the amounts of factor IX_a and factor X present. Pretreatment of factor IX_a with 10 mM diisopropylphosphorofluoridate for 1 h followed by dialysis did not affect the rate of activation. Since factor IX_a is probably the only serine protease involved in blood coagulation that is not sensitive to diisopropylphosphorofluoridate (5, 41), it is unlikely that factor X activation in the above experiment is accomplished by traces of other serine proteases contaminating our factor IX_a preparations.

To allow a kinetic analysis of the reaction, it is necessary to demonstrate that the rate of factor X_a formation is constant in time and increases linearly with the amount of factor IX_a present. That this is the case is shown in Fig. 2. We also obtained constant rates of factor X_a formation proportional to the amount of factor IX_a at higher factor X concentrations and in the absence of calcium ions (data not shown).

The rate of factor X_a formation at various factor X concentrations was determined in the absence of calcium ions and in the presence of 10 mM CaCl₂. The data are presented in the form of Lineweaver-Burk plots (Fig. 3, A and B). In the absence of calcium ions the *K_m* for factor X is 299 μM, and the *V_{max}* of factor X_a formation is 2.2 × 10⁻³ mol of X_a·min⁻¹·




FIG. 1. The Ca²⁺ dependence of factor X activation by factor IX_a in solution. Factor X₂ (31.4 μM) was incubated at 37°C with factor IX_a (1.1 × 10⁻³ μmol/ml) in 200 μl of a buffer containing 50 mM Tris-HCl, 175 mM NaCl, 0.5 mg/ml of ovalbumin at pH 7.9 in the presence of varying amounts of CaCl₂. Varying amounts of extra NaCl were present to compensate for the changes in ionic strength due to the variation of the CaCl₂ concentration. When no CaCl₂ was added the presence of 5 mM EDTA did not influence the rate of factor X_a formation. The rate of factor X_a formation was calculated from the amounts of factor X_a present after 7.5 and 15 min of incubation.




FIG. 2. Time course of factor X activation with different amounts of factor IX_a. Factor X₂ (31.4 μM) was incubated at 37°C with varying amounts of factor IX_a in 200 μl of a buffer containing 50 mM Tris-HCl, 175 mM NaCl, 10 mM CaCl₂, and 0.5 mg/ml of ovalbumin (pH 7.9). After the time intervals indicated, a sample was taken and assayed for factor X_a as described under "Experimental Procedures." The amounts of factor IX_a present were: □—□, 0.55 × 10⁻³ μmol/ml; ●—●, 1.1 × 10⁻³ μmol/ml; ▲—▲, 2.2 × 10⁻³ μmol/ml; ■—■, 6.6 × 10⁻³ μmol/ml.

mol of IX_a⁻¹. In the presence of 10 mM CaCl₂ the *K_m* is 181 μM, and the *V_{max}* is 10.5 × 10⁻³ mol of X_a·min⁻¹·mol of IX_a⁻¹. The factor X used in these experiments was factor X₂. Hence all subsequent experiments reported in this paper are carried out with factor X₂ as substrate.

The Kinetics of Factor X Activation in the Presence of Phospholipid and Calcium Ions—The time course of factor X activation by factor IX_a in the presence of calcium ions and varying factor X and phospholipid concentrations is shown in Fig. 1.³ To obtain a linear time course of factor X activation

³ Portions of this paper (including Figs. 1*–5*) are presented in miniprint at the end of this paper. Miniprint is easily read with the




FIG. 3. Lineweaver-Burk plots of factor X activation by factor IX_a in the presence and absence of $CaCl_2$. Factor X_a formation at varying concentrations of factor X₂ was measured at pH 7.9 at 37°C in 200 μ l of a reaction mixture containing 50 mM Tris-HCl, 175 mM NaCl, ovalbumin (0.5 mg/ml), factor IX_a (1.1×10^{-3} μ mol/ml). A, in the presence of 5 mM EDTA, and B, in the presence of 10 mM

$CaCl_2$. The reaction was started by the addition of factor IX_a . After 7.5 and 15 min samples were taken and assayed for factor X_a as described under "Experimental Procedures." From the amounts of factor X_a found, the rate of factor X_a formation was calculated. The kinetic constants calculated are summarized in Table III.

it is essential to preincubate the phospholipid vesicles for 10 min at 37°C in the presence of 50 mM $CaCl_2$. As can be seen the rate of factor X activation is linear at factor X concentrations well below and above the K_m determined at the respective phospholipid concentrations (see below).

Jesty *et al.* (33, 42) and Fujikawa *et al.* (43) have shown that factor X_a is able to catalyze a number of feedback reactions on the substrate factor X, especially in the presence of phospholipid and calcium ions. Factor X_a can cleave a small glycopeptide from the carboxyl-terminal end of the heavy chain of factor X, giving rise to so-called β factor X. Factor X_a is also able to convert both factor X and β factor X autocatalytically into, respectively, α factor X_a and β factor X_a by hydrolyzing a specific peptide bond in the NH_2 -terminal region of the heavy chain. This second feedback reaction especially may interfere with the determination of the rate of factor X activation by factor IX_a . It is possible, however, to select experimental conditions such that factor X activation by factor X_a is negligible compared to the contribution by factor IX_a . The low amounts of factor X_a formed in our experiments (0.05–2 pmol/ml) can easily be detected on the Aminco DW2 spectrophotometer. When these amounts of factor X_a are incubated with calcium ions, phospholipid, and factor X under the conditions employed in our kinetic experiments, no extra factor X_a formation is detectable. As an extra control an aliquot of the reaction mixture (see legend to Fig. 1*) taken after 30 min was analyzed by polyacrylamide gel electrophoresis in the presence of sodium dodecyl sulfate. The only protein that could be seen on the gel was factor X (data not shown), and no β factor X or factor X_a is detectable. From these control experiments we conclude that the factor X_a formation we measure in our experiments results from the action of factor IX_a on α factor X.

The Ca^{2+} dependence of the rate of factor X_a formation at various phospholipid concentrations is shown in Fig. 4. The titration curves are sigmoidal, and the optimal Ca^{2+} concentration slightly increases with increasing phospholipid concentrations. The Ca^{2+} optimum is, however, independently of the




FIG. 4. The Ca^{2+} dependence of factor X activation by factor IX_a in the presence of phospholipid. Phospholipid vesicles were incubated at 37°C in 0.3 ml of a buffer containing 50 mM Tris-HCl (pH 7.9), 100 mM NaCl, 0.5 mg/ml of ovalbumin, and varying amounts of $CaCl_2$. The ionic strength was kept constant by the addition of extra NaCl. After 10 min, 0.95 ml of factor X (2.0 μ M) was added, and 4 min later, factor X activation was started by the addition of 0.25 ml of factor IX_a (0.09 μ M). Both proteins were dissolved in a buffer containing 50 mM Tris-HCl (pH 7.9), 100 mM NaCl, and 0.5 mg/ml of ovalbumin. The final reaction mixture contained 50 mM Tris-HCl (pH 7.9), 0.5 mg/ml of ovalbumin, an amount of NaCl to bring the ionic strength at 0.21, $CaCl_2$ as indicated in the figure, 1.27 μ M factor X, 1.5×10^{-5} μ mol/ml of factor IX_a and \blacktriangle — \blacktriangle , 25 μ M phospholipid; \bullet — \bullet , 50 μ M phospholipid; \triangle — \triangle , 200 μ M phospholipid; and \circ — \circ , 400 μ M phospholipid. The rates of factor X_a formation were calculated from the amount of factor X_a present in the reaction mixture after 7.5 and 15 min. Phospholipid vesicles were prepared as described under "Experimental Procedures."

amounts of factor IX_a and factor X present. When the factor IX_a concentration is varied at a constant amount of factor X, calcium ions, and phospholipid, the rate of factor X activation observed is directly proportional to the factor IX_a concentration (Fig. 2*).

The dependence of the rate of factor X_a formation on the factor X concentration was determined at 10 mM $CaCl_2$ and various phospholipid concentrations. A set of Lineweaver-Burk plots was obtained, two of which are shown in Fig. 5. An interesting feature of the Lineweaver-Burk plots shown in Fig. 5 is the hockey stick shape of the plot. Above a certain factor

aid of a standard magnifying glass. Full size photocopies are available from the Journal of Biological Chemistry, 9650 Rockville Pike, Bethesda, MD 20014. Request Document 80M-1626, cite author(s), and include a check or money order for \$2.00 per set of photocopies. Full size photocopies are also included in the microfilm edition of the Journal that is available from Waverly Press.

X concentration, no further increase of the rate of factor X_a formation is observed. The factor X concentration at which the Lineweaver-Burk plot levels off increases with the phospholipid concentration. A number of explanations is possible for this phenomenon. Since they depend on the model for the mode of action of phospholipid in the factor X-activating complex, the explanations will be treated in the discussion. For calculation of the kinetic parameters K_m and V_{max} , we only used experimental points where the rate of factor X activation is still dependent on the amount of factor X present.

At 20 μM phospholipid the K_m for factor X is 0.14 μM , and the V_{max} of factor X_a formation is 5.8×10^{-3} mol of $X_a \cdot \text{min}^{-1} \cdot \text{mol}$ of IX_a^{-1} . The rates are expressed per mol of factor IX_a added. Compared with the results obtained in solution, it is seen that phospholipid lowers the K_m for factor X about 2000-fold with only little effect on the V_{max} of factor X_a formation. The kinetic constants determined at different phospholipid concentrations are summarized in Table I. There is a gradual increase of the K_m for factor X when the phospholipid concentration is raised. The V_{max} of factor X_a formation also increases with the phospholipid concentration. The variation of V_{max} may be due to the fact that the V_{max} is calculated from the amount of factor IX_a added, while it is actually the amount of factor IX_a bound to the phospholipid surface at each phospholipid concentration that determines the rate of factor X activation. The kinetic parameters of factor X activation in solution are such that free factor IX_a does not contribute to factor X_a formation. Therefore, a variation of the amount of factor IX_a bound due to the variation of the phospholipid concentration will then be reflected in the observed value of V_{max} . In that case extrapolation of a double reciprocal plot ($1/V_{max}$ versus $1/[\text{phospholipid}]$) at a constant factor IX_a to infinite phospholipid concentration yields the V_{max} for bound factor IX_a (Fig. 3*). The V_{max} calculated from this plot is 0.08 mol of $X_a \cdot \text{min}^{-1} \cdot \text{mol}$ of IX_a^{-1} (bound).




FIG. 5. Lineweaver-Burk plots of factor X activation by factor IX_a in the presence of phospholipid. Phospholipid vesicles were preincubated at 37°C in a buffer containing 50 mM Tris-HCl, 175 mM NaCl, and 50 mM CaCl_2 at pH 7.9. After 10 min, 0.1 ml of the phospholipid mixture was transferred to 0.35 ml of a buffer containing 50 mM Tris-HCl (pH 7.9), 175 mM NaCl, 0.5 mg/ml of ovalbumin, and varying amounts of factor X. Four min later, factor X activation was started by the addition of 0.05 ml of factor IX_a (0.11 μM). The final reaction mixture contained: 50 mM Tris-HCl (pH 7.9), 175 mM NaCl, 0.4 mg/ml of ovalbumin, 10 mM CaCl_2 , 1.09×10^{-5} $\mu\text{mol}/\text{ml}$ of IX_a , varying amounts of factor X, and \blacktriangle — \blacktriangle , 50 μM phospholipid; \bullet — \bullet , 200 μM phospholipid. The rate of factor X_a formation was calculated from the amount of factor X_a present in the reaction mixture after 7.5 and 15 min. Phospholipid vesicles were prepared as described under "Experimental Procedures." The kinetic parameters calculated are summarized in Table I.

TABLE I

Effect of phospholipid on kinetic parameters of factor X activation

| Phospholipid | K_m^{app} | V_{max} |
|---------------|--------------------|--|
| μM | | $\text{mol } X_a \cdot \text{min}^{-1} \cdot \text{mol } \text{IX}_a^{-1}$ |
| 10 | 0.058 | 0.00247 |
| 20 | 0.139 | 0.00579 |
| 50 | 0.363 | 0.0226 |
| 75 | 0.409 | 0.0219 |
| 100 | 0.525 | 0.0231 |
| 150 | 0.822 | 0.0295 |
| 200 | 1.83 | 0.0474 |
| 300 | 1.76 | 0.0437 |

The Kinetics of Factor X Activation in the Presence of Phospholipid and Factor VIII_a—From many reports in the literature, it is obvious that factor VIII participates in the factor X-activating complex in an activated form (15, 18, 22). The activity of factor VIII in the intrinsic factor X activation is considerably enhanced by prior incubation with trace amounts of thrombin. The effect of thrombin on the activity of factor VIII is evaluated in general with a clotting assay. Feedback reactions by thrombin and other serine proteases accumulating during clotting hamper a study of the quantitative aspect of this activation. Therefore, we aimed to set up a system in which the activation of factor VIII by thrombin can be followed directly by measuring its effect on factor X activation.

The experimental set-up is as follows. Factor VIII is incubated with varying amounts of thrombin, and the time course of activation is followed by transferring after different time intervals aliquots of this activation mixture to a reaction mixture containing a small amount of factor IX_a (2000 times lower than in the experiments of the previous section), factor X, CaCl_2 , and phospholipid. From the amount of factor X_a formed after 2, 3, and 4 min in this mixture, the rate of factor X_a formation is calculated. This rate is taken as a measure of the amount of factor VIII_a present in the aliquot.

The time course of factor VIII activation by various amounts of thrombin was measured with this assay and is shown in Fig. 4*. Incubation of factor VIII with thrombin results in a rapid increase of factor VIII_a activity followed by a decrease. Both the rates of activation and inactivation increase with the thrombin concentration. When either factor VIII or thrombin is omitted from the activation mixture no factor X_a is formed in the reaction mixture. This experiment stresses again that factor VIII has to be activated before it can exert its stimulating effect on the activation of factor X by factor IX_a .

We were unable to show activation of factor VIII by factor X_a either in the presence or in the absence of phospholipid and calcium ions. This is in contrast with earlier reported findings (16, 18) that factor X_a can activate factor VIII. We have to emphasize, however, that the amount of factor X_a is limited to 0.5 $\mu\text{g}/\text{ml}$, since higher amounts of factor X_a cause autocatalytic factor X activation in the assay system.

In our further experiments, factor VIII is activated by incubation with 0.04 μg of thrombin/ml for 5 min at 37°C.

The time course of factor X activation in the presence of factor VIII_a , calcium ions, and 5, 10, or 25 μM phospholipid was determined at a low and a high factor X concentration (Fig. 6). Factor VIII_a , activated as described above, was added to a mixture of phospholipid (pretreated with CaCl_2), CaCl_2 , factor IX_a , and factor X preincubated 3 min at 37°C. A typical time course of factor X activation shows a lag period of 1–2 min, a 4-min period with an apparent constant rate of factor X_a formation followed by a decrease of the activation rate. We have been unable to shorten the lag period by changing the




FIG. 6. Time course of factor X activation by factor IX_a in the presence of phospholipid, factor VIII_a, and CaCl₂. Factor VIII (20 units/ml) was activated at 37°C with 0.04 mg/ml of thrombin. After 5 min 0.5 ml of the activation mixture was added to 0.5 ml of a reaction mixture containing 50 mM Tris-HCl (pH 7.9), 175 mM NaCl, 10 mM CaCl₂, 1 mg/ml of ovalbumin, 0.68×10^{-8} μmol/ml of factor IX_a, and various amounts of phospholipid and factor X at 37°C. Before use, phospholipid vesicles were incubated 10 min at 37°C in a buffer containing 50 mM Tris, 175 mM NaCl, and 50 mM CaCl₂ at pH 7.9. After the time intervals indicated in the figure aliquots from this activation mixture were taken and assayed for factor X_a. The final activation mixture contained 50 mM Tris (pH 7.9), 175 mM NaCl, 5 mM CaCl₂, 0.5 mg/ml of ovalbumin, 0.34×10^{-8} μmol/ml of IX_a, factor VIII_a, and ●—●, 5 μM phospholipid, 0.005 μM factor X; ▲—▲, 10 μM phospholipid, 0.01 μM factor X; ■—■, 25 μM phospholipid, 0.025 μM factor X (A) or ●—●, 5 μM phospholipid, 0.05 μM factor X; ▲—▲, 10 μM phospholipid, 0.1 μM factor X; ■—■, 25 μM phospholipid, 0.25 μM factor X (B). Phospholipid vesicles were prepared as described under "Experimental Procedures."

preincubation conditions or the order of addition of the components of the factor X-activating mixture. The time course of factor X_a formation did not change when extra factor X_a (up to amounts formed in the above experiment) was included in the reaction mixture. We have no explanation for the observed lag period. The decrease of the rate of factor X_a formation after 5 min is probably caused by inactivation of factor VIII_a, since addition of extra factor VIII_a to the reaction mixture restores the ability to activate factor X (data not shown).

In all subsequent experiments, we calculated the rate of factor X_a formation in the presence of factor VIII_a over the 4-min time interval during which the rate was constant. The Ca²⁺ titration curve of factor X activation by factor IX_a in the presence of 5 and 25 μM phospholipid and factor VIII_a were similar to those measured in the absence of factor VIII_a (cf. Fig. 4). The curves were also sigmoidal, and the optimal Ca²⁺ concentration under these conditions is about 7.5 mM at both phospholipid concentrations.

When the factor IX_a concentration is varied at a constant amount of factor X, CaCl₂, phospholipid, and factor VIII_a, the rate of factor X activation observed is directly proportional to the factor IX_a concentration (Fig. 5*).

Having established the best experimental conditions for measurement of factor X activation with the complete factor X-activating complex, Lineweaver-Burk plots were made at 10 μM phospholipid with various amounts of factor VIII_a present (Fig. 7). The kinetic parameters that are obtained from these plots are summarized in Table II. At high factor VIII_a concentrations the K_m for factor X is 0.063 μM, and the V_{max} is 500 mol of X_a·min⁻¹·mol of IX_a⁻¹. When the same experiment was carried out in the absence of factor VIII_a, the K_m was 0.058 μM and the V_{max} was 0.0025 mol of X_a·min⁻¹·mol of IX_a⁻¹ (see Table I). It is obvious that the presence of factor VIII_a hardly affects the K_m for factor X but increases




FIG. 7. Lineweaver-Burk plots of factor X_a formation by factor IX_a in the presence of phospholipid and varying amounts of factor VIII_a. Factor VIII (20 units/ml) was activated at 37°C with 0.04 μg/ml of thrombin in a buffer containing 50 mM Tris-HCl and 175 mM NaCl at pH 7.9. After 5 min of incubation varying amounts of this incubation mixture were added to a reaction mixture containing the further components for factor X activation in such amounts that the final concentrations in the reaction mixture (1 ml) became 50 mM Tris-HCl (pH 7.9), 175 mM NaCl, 7.5 mM CaCl₂, 0.5 mg/ml of ovalbumin, 0.34×10^{-8} μmol/ml of factor IX_a, 10 μM phospholipid, varying amounts of factor X, and ■—■, 2 units/ml of factor VIII, ▲—▲, 8 units/ml of factor VIII, and ●—●, 11 units/ml of factor VIII. At 2, 3, and 4 min after addition of factor VIII to the reaction mixture, aliquots were taken and assayed for factor X_a. The rate of factor X_a formation was calculated from the amounts of factor X_a present in these aliquots. The phospholipid vesicles present in the reaction mixture were prepared as described under "Experimental Procedures" and were incubated for 10 min at 37°C in 50 mM Tris-HCl (pH 7.9) and 175 mM NaCl before addition to the reaction mixture. The kinetic parameters calculated are summarized in Table II.

TABLE II
Effect of factor VIII_a and phospholipid on the kinetic parameters of factor X activation

| Phospholipid | VIII _a | K_m^{app} | V_{max} |
|--------------|-------------------|-------------|--|
| μM | units/ml | μM | mol X _a ·min ⁻¹ ·mol IX _a ⁻¹ |
| 10 | 2 | 0.018 | 207 |
| 10 | 4 | 0.022 | 309 |
| 10 | 8 | 0.036 | 497 |
| 10 | 11 | 0.063 | 500 |
| 10 | 8 | 0.024 | 198 |
| 5 | 8 | 0.045 | 439 |
| 10 | 8 | 0.083 | 436 |
| 25 | 8 | | |

the V_{max} of factor X_a formation about 200,000-fold. The V_{max} increases with the amount of factor VIII_a added (Table II). At high concentrations of factor VIII the rate of activation is not further increased, indicating that it is possible to add saturating amounts of factor VIII_a.

In a model in which factor VIII_a is the cofactor of the enzyme factor IX_a, factor IX_a is saturated with factor VIII_a, and an optimal concentration of factor IX_a-factor VIII_a complex is formed. It is a question, however, whether the model is as simple as that, since the amount of factor VIII_a present also influences the K_m for factor X that is measured (Table II). For this phenomenon we have no obvious explanation yet.

Lineweaver-Burk plots in the presence of factor VIII_a (8 units/ml) were made at three different phospholipid concentrations (Fig. 8). The kinetic constants obtained from these




FIG. 8. Lineweaver-Burk plots of factor X_a formation by factor IX_a in the presence of factor $VIII_a$ and varying amounts of phospholipid. The rate of factor X_a formation at various factor X concentrations was measured at \bullet — \bullet , 5 μM phospholipid, \blacksquare — \blacksquare , 10 μM phospholipid, and \blacktriangle — \blacktriangle , 25 μM phospholipid in the presence of activated factor VIII (8 units/ml) and $CaCl_2$ (7.5 mM). For experimental details, see legend to Fig. 7.

plots are also summarized in Table II. The K_m for factor X appears to be dependent on the phospholipid concentration to the same extent as observed in the experiments carried out in the absence of factor $VIII_a$ (cf. Table I).

Kinetics of Activation of Factor X_1 and β Factor X—Since all experiments reported in this paper were carried out with factor X_2 , we were interested whether factor X_1 and β factor X are kinetically identical. Therefore, a number of experiments were repeated using factor X_1 and factor βX as substrate. Both factor X_1 and βX showed the same kinetics of activation as factor X_2 .

DISCUSSION

Previous studies on the intrinsic activation of factor X suggest that the activator is a complex composed of factor IX_a , factor $VIII_a$, phospholipid, and calcium ions (4–11, 22, 23). Several properties of factor IX_a indicate that it is a serine protease and hence will be the enzyme that actually activates factor X. Factor IX_a is highly homologous to other serine proteases involved in blood coagulation (13) and has an esterase activity toward synthetic arginine esters (44). Its enzymatic activity is also inhibited by well known serine protease inhibitors like antithrombin III (44, 45) and hirudin (46).

When it is accepted that factor IX_a is the enzyme in the factor X-activating complex it is plausible to assume that factor VIII, phospholipid, and calcium ions act as cofactors to factor IX_a . In this concept the roles of factor IX_a , factor VIII, and phospholipid are analogous to those of, respectively, factor X_a , factor V_a , and phospholipid in the prothrombin-activating complex.

If this model is correct one would expect that factor IX_a can activate factor X in the absence of accessory components. Although no activation of factor X by factor IX_a in solution has been reported yet, Hultin and Nemerson (22) have shown that factor IX_a in the presence of phospholipid and calcium ions, but without factor VIII, slowly activates factor X. The rate of factor X activation was substantially increased when thrombin-activated factor VIII was included in the reaction mixture. A rate enhancement caused by factor VIII has been reported in several other papers (1, 20, 22, 23). These findings extend the analogy with the prothrombin-activating complex. The accessory components phospholipid and factor $VIII_a$ stimulate factor X activation by factor IX_a , just as phospho-

lipid and factor V_a increase the rate of conversion of prothrombin to thrombin by factor X_a (47, 48).

In this paper we report that factor IX_a in solution, in the absence of accessory components, is able to catalyze the activation of factor X. This finding supports the concept that factor IX_a is the enzyme in the intrinsic factor X-activating complex. It proved possible to carry out a kinetic study and obtain the kinetic parameters (K_m and V_{max}) for the activation reaction in solution. We determined a K_m for factor X of 299 μM and a V_{max} of 2.2×10^{-3} mol of $X_a \cdot \text{min}^{-1} \cdot \text{mol}$ of IX_a^{-1} . The presence of calcium ions has little effect on the kinetic parameters (Table III).

The fact that we were able to study the kinetics of the reaction in solution made it possible to determine the effect of phospholipid and factor $VIII_a$ on the kinetic parameters of factor X activation. Such a kinetic analysis offers the opportunity to gain insight into the role of phospholipid and factor $VIII_a$ in the mechanism of factor X activation. Knowledge of the kinetic parameters is also essential to evaluate the contribution of intrinsic factor X activation to factor X_a formation at physiological conditions.

The kinetic parameters for different factor X-activating mixtures are summarized in Table III. Both phospholipid and factor $VIII_a$ cause important changes of the kinetic parameters of factor X activation. In the presence of 10 μM phospholipid the K_m drops from 181 μM to 0.058 μM , while there is little change of the V_{max} . The effect of factor $VIII_a$ is mainly restricted to the V_{max} . In the presence of factor $VIII_a$ the V_{max} increases about 200,000-fold.

The data presented in this report have important implications for the mode of action of phospholipid in the mechanism of intrinsic factor X activation. Phospholipid has little effect on the catalytic activity of factor IX_a . For free factor IX_a a V_{max} of 0.01 mol of $X_a \cdot \text{min}^{-1} \cdot \text{mol}$ of IX_a^{-1} is measured (Table III), and for phospholipid-bound factor IX_a the V_{max} is 0.08 mol of $X_a \cdot \text{min}^{-1} \cdot \text{mol}$ of IX_a^{-1} . The K_m for factor X is dramatically decreased in the presence of phospholipid. There is, however, a considerable increase of the K_m at higher phospholipid concentrations, so a K_m measured in the presence of phospholipid has to be regarded as an apparent K_m . In a previous paper (24), we have shown that in the prothrombinase complex phospholipid causes a marked decrease of the K_m for prothrombin, and the K_m is also raised at increasing phospholipid concentrations. Hence it seems plausible that the mechanistic basis for the mode of action of phospholipid in both complexes is identical. Two models have been proposed to explain the role of phospholipid in prothrombin activation. Because of the similarity between prothrombin and factor X activation with respect to phospholipid involvement, these models are also applicable to factor X activation. In previous papers (24, 49), we suggested that the enzyme and substrate are bound to the phospholipid surface and that the amount of bound substrate determines the rate of activation. An increased local substrate concentration at or in the vicinity

TABLE III

Effect of the accessory components on kinetic parameters of factor X activation

| Composition of factor X-activating mixture | K_m^{app} μM | V_{max} $\text{mol } X_a \cdot \text{min}^{-1} \cdot \text{mol } IX_a^{-1}$ |
|---|------------------------|--|
| IX_a | 299 | 0.0022 |
| $IX_a, CaCl_2$ | 181 | 0.0105 |
| $IX_a, CaCl_2, PL^a$ (10 μM) | 0.058 | 0.00247 |
| $IX_a, CaCl_2, PL$ (10 μM), $VIII_a$ (11 units/ml) | 0.063 | 500 |

^a PL, phospholipid.

of the phospholipid surface (cf. Ref. 50) can explain the large decrease of the K_m observed in the presence of phospholipid. The K_m measured, expressed in terms of added substrate, is an apparent K_m , which increases when increasing amounts of phospholipid are present, since at higher phospholipid concentrations more substrate has to be added to attain the local concentration at which the enzyme bound to the surface works at $\frac{1}{2} V_{max}$. A different model is proposed by Nelsestuen (51). He suggests that the enzyme bound at the phospholipid surface is active on the soluble substrate. Phospholipid causes a decrease of the apparent K_m by altering the binding affinity of the active site of the enzyme for its substrate. Although Nelsestuen does not mention in his paper the increase of the apparent K_m at higher phospholipid concentration, this can also be explained in this model. Binding of the substrate reduces the concentration in solution. At a higher phospholipid concentration more substrate is bound, and hence more substrate has to be added to reach a substrate level in solution at which the enzyme functions at $\frac{1}{2} V_{max}$. It will be obvious that both models can qualitatively explain the effect of phospholipid on the K_m for factor X of the intrinsic factor X activator reported in this paper. The flattening of the Lineweaver-Burk plots observed at high factor X concentrations is most easily explained in the model where bound factor X is the substrate. At high factor X concentrations the binding sites for factor X at the phospholipid vesicles become saturated. The addition of extra factor X cannot further increase the bound factor X concentration, and consequently there is no further increase in the rate of activation. At higher phospholipid concentration more factor X is required to saturate the binding sites, and hence the leveling off occurs at a higher factor X concentration. It is interesting to notice that the break point in the Lineweaver-Burk plots is observed at factor X concentrations about equal to the concentration of binding sites for factor X present on the kind of phospholipid vesicles used in our experiments ($0.011 \mu\text{M}$ binding sites/ μM phospholipid; Ref. 52). A qualitative explanation of the above phenomenon in the model where soluble factor X is the substrate is not readily available. In order to determine which of the two models is valid, the exact binding parameters of factor X binding to the phospholipid vesicles under the conditions of our kinetic experiments have to be known. In that case the amounts of bound and free factor X at each individual point of the Lineweaver-Burk plot can be calculated, and it can be verified whether the reaction obeys Michaelis-Menten kinetics with bound or soluble substrate. At the moment experiments are underway in our laboratory in which binding and kinetic parameters for various phospholipid mixtures are determined under identical conditions with the aim to discriminate between the two models.

Factor VIII_a enormously stimulates the V_{max} of factor X activation. No activation of factor X can be detected by factor VIII_a alone. Since factor IX_a, even in the absence of accessory components, can catalyze the formation of factor X_a, we conclude that factor VIII_a acts as a co-factor to accelerate an enzymatic reaction which already occurs in its absence. Factor VIII has to be activated with thrombin to accomplish its stimulatory effect on the V_{max} . When factor VIII_a is replaced by factor VIII in an experiment carried out at a saturating factor VIII_a concentration, the rate of factor X activation is below 1% of that measured with factor VIII_a. The remaining activity cannot be explained by the action of factor IX_a alone. Since our unactivated factor VIII preparation may contain small amounts of factor VIII_a, we cannot determine whether native factor VIII can support factor X activation. The V_{max} rises when increasing amounts of factor VIII_a are present. At high concentrations of factor VIII_a the V_{max} is not further

increased, which in the co-factor model for factor VIII_a would mean that factor IX_a becomes saturated with co-factor. Under these conditions factor IX_a has a proteolytic activity comparable to factor X_a in the prothrombin-activating complex (24, 53) and to factor VII_a in the extrinsic factor X-activating complex (21) determined in the presence of saturating amounts of their respective co-factors V_a and tissue factor. For the increase of the K_m for factor X observed at increasing factor VIII_a concentrations we have no interpretation yet. A more extensive kinetic analysis will be required to explain this phenomenon. The high molecular weight form of factor VIII was used in the experiments described in this paper. This preparation, generally referred to as factor VIII/von Willebrand factor (factor VIII/vWF) is a complex of low molecular weight factor VIII coagulant activity and high molecular weight von Willebrand platelet aggregating activity. Recently, Vehar and Davie (18) succeeded in obtaining a highly purified factor VIII coagulant activity. It will be interesting to compare the effects of factor VIII coagulant activity and factor VIII/vWF on the kinetics of factor X activation.

The physiological significance of the alteration of kinetic parameters will be obvious. Intrinsic factor X activation requires phospholipid because it lowers the K_m for the substrate to within the range of the plasma concentration ($0.2 \mu\text{M}$). At high phospholipid concentrations the K_m rises, however, above the plasma factor X concentration. It is possible that this phenomenon plays a role in the physiologic regulation of factor X_a formation. Factor VIII_a via its effect on V_{max} increases the rate of factor X activation to a level where sufficient factor X_a is formed to control hemostasis. It is interesting to compare the kinetic parameters that we found for the intrinsic factor X activator with those of the extrinsic factor X activator determined by Silverberg *et al.* (21). They found a K_m for factor X of $0.34 \mu\text{M}$ and a V_{max} of $1900 \text{ mol of X}_a \cdot \text{min}^{-1} \cdot \text{mol of VII}_a^{-1}$. Thus the catalytic efficiency, V_{max}/K_m , for both activator systems is about equal. These data will have to be taken into consideration in a discussion about the contribution of the intrinsic and extrinsic factor X activation to factor X_a formation *in vivo*.

Acknowledgments—We would like to thank Mr. J. H. L. Franssen for the preparation of factor VIII, Mrs. G. W. Janssen-Claessen for excellent technical assistance, Dr. Y. Nemerson for kindly providing the computer program for calculation of the kinetic constants, Mrs. J. W. P. Govers-Riemslog for adaptation of the program, and Professor Dr. R. F. A. Zwaal for stimulating discussions. Part of the chromogenic substrates used in our laboratory were kindly donated by AB Kabi Diagnostica.

REFERENCES

1. Fujikawa, K., Coan, M. H., Legaz, M. E., and Davie, E. W. (1974) *Biochemistry* **13**, 5290-5299
2. Jesty, J., and Nemerson, Y. (1974) *J. Biol. Chem.* **249**, 509-515
3. Davie, E. W., and Fujikawa, K. (1975) *Annu. Rev. Biochem.* **44**, 799-829
4. MacFarlane, R. G., Biggs, R., Ash, B. J., and Denson, K. W. E. (1964) *Br. J. Haematol.* **10**, 530-541
5. Lundblad, R. L., and Davie, E. W. (1964) *Biochemistry*, 1720-1725
6. Schiffman, S., Rapaport, S. I., and Chong, M. M. Y. (1966) *Proc. Soc. Exp. Biol. Med.* **123**, 736-744
7. Hougie, C., Denson, K. W. E., and Biggs, R. (1967) *Thromb. Diath. Haemorrh.* **18**, 211-222
8. Barton, P. G. (1967) *Nature* **215**, 1508-1509
9. Hemker, H. C., and Kahn, M. J. P. (1967) *Nature* **215**, 1201-1202
10. Østerud, B., and Rapaport, S. I. (1970) *Biochemistry* **9**, 1854-1861
11. Varadi, K., and Hemker, H. C. (1976) *Thromb. Res.* **8**, 303-317
12. Bucher, K., Nebelin, E., Thomsen, J., and Stenflo, J. (1976) *FEBS Lett.* **68**, 293-296
13. Katayama, K., Ericsson, L. H., Enfield, D. L., Walsh, K. A., Neurath, H., Davie, E. W., and Titani, K. (1979) *Proc. Natl.*

- Acad. Sci. U. S. A.* **76**, 4990-4994
14. Hemker, H. C., Kahn, M. J. P., and Devilee, P. P. (1970) *Thromb. Diath. Haemorrh.* **24**, 214-223
 15. Østerud, B., Rapaport, S. I., Schiffman, S., and Chong, M. M. Y. (1971) *Br. J. Haematol.* **21**, 643-660
 16. Davie, E. W., Fujikawa, K., Legaz, M. E., and Kato, H. (1975) *Cold Spring Harbor Conf. Cell Proliferation* **2**, 65-72
 17. Vehar, G. A., and Davie, E. W. (1977) *Science* **197**, 374-376
 18. Vehar, G. A., and Davie, E. W. (1980) *Biochemistry* **19**, 401-410
 19. Zwaal, R. F. A. (1978) *Biochim. Biophys. Acta* **515**, 163-205
 20. Suomela, H., and Blombäck, B. (1977) *Thromb. Res.* **1**, 267-281
 21. Silverberg, S. A., Nemerson, Y., and Zur, M. (1977) *J. Biol. Chem.* **252**, 8481-8488
 22. Hultin, M. B., and Nemerson, Y. (1978) *Blood* **52**, 928-940
 23. Brown, J. E., Baugh, R. F., and Hougie, C. (1978) *Thromb. Res.* **13**, 893-900
 24. Rosing, J., Tans, G., Govers-Riemslog, J. W. P., Zwaal, R. F. A., and Hemker, H. C. (1980) *J. Biol. Chem.* **255**, 274-283
 25. Cuatrecasas, P. (1970) *J. Biol. Chem.* **245**, 3059-3065
 26. Fujikawa, K., Thompson, A. R., Legaz, M. E., Meyer, R. G., and Davie, E. W. (1973) *Biochemistry* **12**, 4938-4945
 27. Fujikawa, K., Legaz, M. E., and Davie, E. W. (1972) *Biochemistry* **11**, 4882-4891
 28. Nossel, H. L. (1964) *The Contact Phase of Blood Coagulation*, Blackwell Scientific Publication, Oxford
 29. Østerud, B., and Rapaport, S. I. (1977) *Proc. Natl. Acad. Sci. U. S. A.* **74**, 5260-5264
 30. Schiffman, S., Theodor, I., and Rapaport, S. I. (1969) *Biochemistry* **8**, 1397-1405
 31. Fujikawa, K., Legaz, M. E., and Davie, E. W. (1972) *Biochemistry* **11**, 4892-4899
 32. Fujikawa, K., Legaz, M. E., Kato, H., and Davie, E. W. (1974) *Biochemistry* **13**, 4508-4516
 33. Jesty, J., Spencer, A. K., and Nemerson, Y. (1974) *J. Biol. Chem.* **249**, 5614-5622
 34. Schmer, G., Kirby, E. P., Teller, D. C., Davie, E. W. (1972) *J. Biol. Chem.* **247**, 2512-2521
 35. Van Mourik, J. A., and Mochtar, I. A. (1970) *Biochim. Biophys. Acta* **221**, 667-679
 36. Chantarangkul, V., Ingram, G. I. C., Thorn, M. B., and Darby, S. C. (1978) *Br. J. Haematol.* **40**, 471-488
 37. Smith, R. L. (1973) *J. Biol. Chem.* **248**, 2418-2423
 38. Byrne, R., Link, R. P., and Castellino, F. J. (1980) *J. Biol. Chem.* **255**, 5336-5341
 39. Jackson, C. M., Johnson, T. F., and Hanahan, D. J. (1968) *Biochemistry* **7**, 4492-4505
 40. Eisenthal, R., and Cornish-Bowden, A. (1974) *Biochem. J.* **139**, 715-720
 41. Aronson, D. L. (1974) *Thromb. Diath. Haemorrh.* **559**, 11-26
 42. Jesty, J., Spencer, A. K., Nakashima, Y., Nemerson, Y., and Konigsberg, W. (1975) *J. Biol. Chem.* **250**, 4497-4504
 43. Fujikawa, K., Titani, K., and Davie, E. W. (1975) *Proc. Natl. Acad. Sci. U. S. A.* **72**, 3359-3363
 44. Kurachi, K., Fujikawa, K., Schmer, G., and Davie, E. W. (1976) *Biochemistry* **15**, 373-377
 45. Rosenberg, J. S., McKenna, P. W., and Rosenberg, R. D. (1975) *J. Biol. Chem.* **250**, 8883-8888
 46. Davie, E. W., Fujikawa, K., Kurachi, K., and Kisiel, W. (1979) *Adv. Enzymol.* **48**, 277-318
 47. Jobin, F., and Esnouf, M. P. (1967) *Biochem. J.* **102**, 666-674
 48. Esmon, C. T., Owen, W. G., and Jackson, C. M. (1974) *J. Biol. Chem.* **249**, 8045-8047
 49. Zwaal, R. F. A., Rosing, J., Tans, G., Bevers, E. M., and Hemker, H. C. (1980) in *The Regulation of Coagulation* (Mann, K. G., and Taylor, F. B., eds) pp. 95-112, Elsevier/North-Holland, New York
 50. Nemerson, Y., Zur, M., Bach, R., and Gentry, R. (1980) in *The Regulation of Coagulation* (Mann, K. G., and Taylor, F. B., eds) pp. 193-202, Elsevier/North-Holland, New York
 51. Nelsestuen, G. L. (1980) in *The Regulation of Coagulation* (Mann, K. G., and Taylor, F. B., eds) pp. 31-41, Elsevier/North-Holland, New York
 52. Nelsestuen, G. L., and Broderius, M. (1977) *Biochemistry* **16**, 4172-4177
 53. Nesheim, M. E., Taswell, J. B., and Mann, K. G. (1979) *J. Biol. Chem.* **254**, 10952-10962

Supplementary material to

THE ROLE OF PHOSPHOLIPID AND FACTOR VIII_a IN THE ACTIVATION OF BOVINE FACTOR X

Gerbrand van Dieijen, Guido Tans, Jan Rosing and H. Coenraad Hemker




Fig. 1^a - Time course of factor X activation by factor IX_a in the presence of phospholipid and CaCl₂. Phospholipid vesicles were incubated 10 min at 37°C in a buffer containing 50 mM Tris-HCl, 175 mM NaCl and 50 mM CaCl₂ (pH 7.9). 0.15 ml of this phospholipid suspension was added to 1.2 ml of a reaction mixture containing 50 mM Tris-HCl, 175 mM NaCl, 0.5 mg/ml ovalbumin and factor X (amounts indicated below) at pH 7.9 and 37°C. After 3 min, factor X activation was started by the addition of 0.15 ml factor IX_a (0.067 μM). The final reaction mixture contained: 50 mM Tris-HCl, 175 mM NaCl, 10 mM CaCl₂, 0.45 mg/ml ovalbumin, 6.7x10⁻⁶ μmoles/ml factor IX_a and Δ—Δ, 10 μM phospholipid, 0.02 μM factor X; ■—■, 10 μM phospholipid, 0.1 μM factor X; ●—●, 100 μM phospholipid, 0.2 μM factor X; ○—○, 100 μM phospholipid, 1.0 μM factor X. After the time intervals indicated in the figure, samples were taken and assayed for factor X_a. Phospholipid vesicles were prepared as described in the experimental procedures.




Fig. 2^a - The effect of factor IX_a on the rate of factor X activation in the presence of phospholipid. Phospholipid vesicles were preincubated at 37°C in 50 mM Tris-HCl, 175 mM NaCl, 50 mM CaCl₂ at pH 7.9. After 10 min, 50 μl of this suspension was transferred to 300 μl of a buffer containing 50 mM Tris-HCl, 175 mM NaCl, 0.5 mg/ml ovalbumin and 0.833 μM factor X at pH 7.9. After 4 min incubation at 37°C, factor X activation was started by the addition of 150 μl 50 mM Tris-HCl (pH 7.9), 175 mM NaCl buffer containing 0.5 mg/ml ovalbumin and various amounts of factor IX_a. The final reaction mixture contained 50 mM Tris-HCl (pH 7.9), 175 mM NaCl, 10 mM CaCl₂, 50 μM phospholipid, 0.5 μM factor X, 0.5 mg/ml ovalbumin and amounts of factor IX_a as indicated in the figure. The rate of factor X activation was calculated from the amounts of factor X_a present in the reaction mixture after 5 and 10 min. The phospholipid vesicles were prepared as described in the experimental procedures.




Fig. 3^a - Double reciprocal plot of V_{max} as a function of the phospholipid concentration. The factor X activating mixture consisted of factor IX_a, CaCl₂ and phospholipid. This plot contains data summarized in Table I.




Fig. 4^a - Time course of activation of factor VIII with various amounts of thrombin. Factor VIII (10 U/ml) was incubated at 37°C with various amounts of thrombin in a buffer containing 50 mM Tris-HCl, 175 mM NaCl at pH 7.9. The amounts of thrombin present are indicated in the figure. After the time intervals indicated in the figure, 0.1 ml of this incubation mixture was transferred to 0.9 ml of a reaction mixture containing all further components required for factor X activation. The final concentrations in the reaction mixture (1 ml) were: 50 mM Tris-HCl (pH 7.9), 175 mM NaCl, 10 mM CaCl₂, 0.5 mg/ml ovalbumin, 0.34 x 10⁻⁸ μmoles/ml factor IX_a, 0.015 μM factor X and 12.5 μM phospholipid. The phospholipid vesicles were preincubated for 10 min at 37°C in a buffer containing 50 mM Tris-HCl, 175 mM NaCl and 50 mM CaCl₂ before addition to the reaction mixture. 2, 3 and 4 min after the addition of factor VIII_a aliquots from the reaction mixture were assayed for factor X_a. The rate of factor X_a formation was calculated from the amounts of factor X_a present in these aliquots. Phospholipid vesicles were prepared as described under "Experimental Procedures".




Fig. 5^a - The effect of factor IX_a on the rate of factor X activation in the presence of factor VIII_a and phospholipid. Factor VIII (10 U/ml) was activated at 37°C with 0.04 μg/ml thrombin in a buffer containing 50 mM Tris-HCl (pH 7.9) and 175 mM NaCl. After 5 min, 0.1 ml of the activation mixture was added to 0.9 ml of a reaction mixture. The final concentrations in the reaction mixture were: 50 mM Tris-HCl (pH 7.9), 175 mM NaCl, 10 mM CaCl₂, 0.5 mg/ml ovalbumin, 0.01 μM factor X, 10 μM phospholipid, factor VIII_a and factor IX_a as indicated. Before use, the phospholipid vesicles were preincubated for 10 min at 37°C in 50 mM Tris-HCl, 175 mM NaCl, 50 mM CaCl₂ at pH 7.9. After 2, 3 and 4 min aliquots were taken from the reaction mixtures and were assayed for factor X_a. The rate of factor X_a formation was calculated from the amount of factor X_a present in these aliquots. Phospholipid vesicles were prepared as described under "Experimental Procedures".